Company intelligence / Profile preview

Edmond Pharma

Paderno Dugnano, Lombardy, Italy

Ownership: Private
Employees: ~18
Development stage: Commercial

Overview

Edmond Pharma manufactures a wide range of generic APIs and finished dosage forms for human and veterinary use. The company has developed proprietary products such as Erdosteine, which is marketed in 40 countries worldwide and has received orphan drug status from the FDA. The company’s manufacturing site is authorized by major health authorities including AIFA, FDA, KFDA, and PMDA. Pipeline programs include Derpanicate for hyperlipidemia (discontinued) and Fenclozine Maleate for fever (pending).

Therapeutic areas: CardiovascularInfectious Diseases
Modalities: Small moleculeGeneric drugsOrphan drugs
Industry: Biotech

Drug pipeline

1 asset

erdosteine

Commercial

Indications: COPD, Chronic bronchitis

Partnerships

Not specified; as a CDMO/API supplier likely partners with multiple pharma companies globally

Beyond the preview

Go deeper on Edmond Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Edmond Pharma.

Explore the full profile